Plaintiff States complaint against Mylan sought damages and injunctive relief, alleging that Mylan conspired with manufacturers of the active ingredient of the anti-anxiety drugs Lorazepam and Clorazepate to monopolize the market through long-term exclusive contracts. The Plaintiff States asserted that such exclusive dealings contracts would substantially impair competition in the anti-anxiety drug market. In addition to a permanent injunction, Mylan agreed to pay $100 million in damages. $71,782,017 was used for payment of consumer claims and $28,217,983 was used for payment of state agency claims. The final $8 million was used to pay for the States investigative costs and attorneys fees. Any residual monies were distributed cy pres to health care organizations. The Federal Trade Commission also participated in the investigation and litigation